Is gosatuzumab (Todavi) a targeted drug? What is its targeted mechanism of action?

Gosatuzumab (Trodelvy) is a targeted drug that is an antibody drug conjugate (ADC). It combines the specificity of antibodies and the potency of chemotherapy drugs to achieve therapeutic effects by precisely targeting cancer cells and releasing cytotoxic drugs. Trodelvyis approved to treat metastatic triple-negative breast cancer (TNBC) and some other cancers, especially after conventional treatments have failed.

Trodelvy's targeting mechanism is based on the specific binding of its antibody moiety (gosatuzumab) to the Trop-2 (tumor-associated calcium signaling molecule 2) receptor on the surface of cancer cells. Trop-2 is a protein overexpressed on the surface of many types of cancer cells, especially in triple-negative breast cancer and some other tumor types. TrodelvyAccurately recognizes and binds to the Trop-2 receptors on the surface of these cancer cells through its antibody part, allowing the drug to be efficiently delivered to the cancer cells.

OnceTrodelvy binds to the Trop-2 receptor, it will be engulfed by cancer cells and enter the cell. Within the cell, Trodelvy's cytotoxic drugs (usually chemotherapy drugs) are released and bind to the DNA in the cell, inhibiting DNA replication and repair, leading to cell death. This mechanism effectively concentrates chemotherapy drugs locally on tumor cells, thereby reducing damage to normal healthy cells and improving the targeting and effectiveness of treatment.

The advantages of Trodelvy are its high targeting and fewer side effects. Traditional chemotherapy drugs often cause toxic reactions on normal cells because their effects are not specific enough. However, gosatuzumab can selectively deliver drugs into tumor cells through antibody-mediated targeting, greatly reducing damage to normal cells. As a result, Trodelvy provides a new treatment option for cancer patients for whom other treatments have not responded well.

Reference materials:https://www.trodelvy.com/